Tissue Proteomic Luncheon at the 2008 ASMS Annual
Meeting, Denver, CO.
Wednesday,
June 4, 12.00-1.00PM
Mining
and Measuring Protein Biomarkers in FFPE Tissue
Hosted
by Expression Pathology Inc. and NextGen Sciences,
Ltd.
Expression Pathology Inc. is developing enabling technologies
for discovery and measurement of protein biomarkers in tissue.
NextGen Sciences, Ltd. is a leading provider of mass spectrometry
based proteomic analysis.
The company has developed a suite of biomarker services
that utilizes proprietary methods to significantly decrease
timelines and increase the success rates traditionally associated
with the various stages of biomarker development.
Working
together the companies provide a full range of tissue
proteomic biomarker discovery, assay developoment and testing
services.
We are proud to host presentations by two leading clinical
proteomics specialists;
12.00 Biomarker Discovery and Quantitation for Tissue Proteomics
Dr. David Krizman, CSO and scientific co-founder of Expression
Pathology
12.35 FFPE Tissue Proteomic Biomarker Discovery and MRM MS-Based
Validation in Early Stage Non-small Cell Lung Cancer
Dr. Toshihide Nishimura, Tokyo Medical University
Seating is limited. Pre-registration
required (click here for registration).
Lunch will be served. We will email you a confirmation and location
information. Please come by our booth, number 21, in Denver.
Dr.
Toshihide Nishimura, Tokyo Medical University, is leading
both the Japanese Society of Clinical Proteomics and the Japanese
HUPO as a Board Member. He is Guest Professor in the 1st Department
of Surgery, Tokyo Medical University, CSO, BiosysTechnologies,
and a Technology Advisor to CANON. He is an expert in mass spectrometry
and proteomics, and is actively collaborating with major pharmaceutical
companies and governmental institutions, including the National
Cancer Center in Japan, on projects related to biomarker discovery
and development in clinical research.
David Krizman, Ph.D., Chief Scientific Officer, is
a scientific co-founder of EPI. Dr. Krizman has been
a pioneer in applications of novel genomics technologies to
tissue while at the National Human Genome Research Institute
and the National Cancer Institute. During his time as a Principal
Investigator at the NCI he co-founded and led the Cancer Genome
Anatomy Project. Dr. Krizman has also served as a scientific
contractor and adviser at the Naval Research Laboratory.
Expression Pathology Inc. (EPI) is a leader in tissue
microproteomics. Our technologies make possible mass spec protein analysis
of formalin-fixed tissue, enabling discovery, validation
and routine
measurement of protein
biomarkers related to clinical outcomes. Our near-term
mission is to offer breakthrough research tools and
collaborations to improve drug
and diagnostic development and for basic research.
Our proprietary technologies also provide the foundation
for a whole new platform of tissue diagnostic
tests currently under development.
The Liquid
Tissue® MS protocol prepares FFPE samples
for mass spec analysis. Complete solubilization captures the entire protein
content. Mass spec friendly. Requires only 30,000 cells for multiple
mass spectrometry analyses.
The Director™ Laser Microdissection Slides
provide the fastest, easiest and most accurate way to collect specific
cellular features from tissue sections. Engineered for use with existing
Leica LMD and PALM Zeiss laser microdissection system.
news sidebar
News & Events
NextGen
Sciences and Expression Pathology to provide protein biomarker
discovery and measurement in tissue, June 30, 2008. (press
release)
Quantitative
Proteomic Analysis of Formalin Fixed Paraffin Embedded Oral HPV Lesions
from HIV Patients, The Open Proteomics Journal, 2008, 1, 40-45,
June 15, 2008. (abstract)
Two
of Expression Pathology's key patents have issued covering
its DIRECTOR™ Slide technology for improved tissue laser microdissection Gaithersburg,
MD. May 19, 2008: (press release).
Expression
Pathology Obtains SBIR to Identify Protein Biomarkers of Breast
Cancer
Metastasis, May 15, 2008 (press
release).
ASMS,
Denver, June 1-5. (link)
Booth 21. Register for our tissue proteomic luncheon
seminar on Wednesday, June 4.
American
Association of Cancer Research, San
Diego, April 12-16. (link)
Booth 2428. See three posters using our technology; discovery
of endometrial cancer markers (write-up),
metastasis marker in melanoma (abstract),
protein biomarkers relating to metastasis and disease progression
in lung cancer (abstract).
A Molecular Portrait of Head and Neck Cancer Progression,
Clin. Cancer Res., Feb. 15, 2008 (abstract)
Expression Pathology Aids Research in Identifying Biomarkers
of Lung Cancer Metastasis and Survival, Feb. 19, 2008 (article
and press release)
Expression Pathology Obtains Maryland Funding to Develop
Breast Cancer Test, Feb. 6, 2008(press
release)
